Clostridioides difficile (C. difficile) is an anaerobic bacterium, widely distributed in soil and the intestinal tracts of animals.
Currently, no vaccine is licensed for the prevention of CDI.
Clostridioides difficile (C. difficile) is an anaerobic bacterium, widely distributed in soil and the intestinal tracts of animals.
Currently, no vaccine is licensed for the prevention of CDI.
The transmission of C. difficile can be patient-to-patient, via contaminated hands of healthcare workers or by environmental contamination.
The clinical spectrum of C. difficile infection (CDI) ranges from mild diarrhoea to severe life-threatening pseudomembranous colitis.
1 in 11 people over age 65 diagnosed with a healthcare-associated C. difficile infection dies within one month.
Nearly 124,000 healthcare-associated C. difficile infections (CDIs) occur annually in acute care hospitals in the EU/EEA, and 3,700 deaths.
Toxoid vaccine (2)
Phase II (1)
Phase III (1)
Paediatric + Adults + Older adults (1)
Older adults (1)
Sources:
Clostridium difficile infections – Facts and surveillance. 2023. Available from: https://www.ecdc. europa.eu/en/clostridium-difficile-infections/facts.
C. diff (Clostridioides difficile). 2024. Available from: https://www.cdc.gov/c-diff/index.html.
[Accessed: August 2024]